TARGEPEUTICS, INC.
GB13, a targeted immunotoxin for glioblastoma treatment
- Sector
- Biotech
- Headquarters
- HUMMELSTOWN, PA
- Latest Form D
- $200K, Jun 2025
- Total capital
- $730K
- Federal grants
- $330K
- 2 awards · 2022–2023
- Rank in peer group#435 of 502
- Private capital raised
- $200K
- 1 Form D · last Jun 2025
- 16 months since last filing
- Federal contracts
- $200K
- 1 award · Health and Human S
- Rank in Biotech#294 of 4373
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$200K
- Federal grantHealth and Human S · Phase I · Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma$55K
- Federal grantHealth and Human S · Phase I · Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma$275K
- Federal contractHealth and Human S · TAS::75 0849::TAS Topic 255 Development Of GB13 As A Novel Glioblastoma Therapy$200K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
164months
from TARGEPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Sep 2011
- Health and Human S · $200K
- First Form D · Jun 2025
- $200K · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#7 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Randy B. SchrecengostResearcherExecutive OfficerLinked by $330K in grants as PI
- Gerard B. SmithDirectorNamed in SEC Form D filings
- Lynn B. MainesDirector, PromoterNamed in SEC Form D filings
- Silvan B. Lutkewitte, IIIExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- PendingMethods Of Treating Malignant GliomasUSPTOApplication 18993145
- PendingMethods Of Treating Malignant GliomasUSPTOApplication 18294303
- PendingHydrogel Compositions For Treatment Of Malignant GliomasUSPTOApplication PCTUS2024051185
Show all 12 patent records
- Methods Of Treating Malignant GliomasJan 22, 2026 · Application 18993145Pending
- Methods Of Treating Malignant GliomasMar 6, 2025 · Application 18294303Pending
- Hydrogel Compositions For Treatment Of Malignant GliomasApplication PCTUS2024051185Pending
- Hydrogel Compositions For Treatment Of Malignant GliomasApplication 63589682Pending
- Methods Of Treating Malignant GliomasApplication PCTUS2023068842Pending
- Methods Of Treating Malignant GliomasApplication PCTUS2022079654Pending
- Methods Of Treating Tumors With Mutagenized IL13Application 63368283Pending
- IL-13Ra2 IMMUNOCONJUGATE TARGETED THERAPY FOR H3K27M-MUTANT MIDLINE GLIOMASApplication 63277866Pending
- Mutagenized IL13 And Methods Of UseApplication PCTUS2019059855Pending
- Noninvasive Tracking Of A Targeted ToxinApplication PCTUS2025044482Pending
- Hydrogel Compositions For Treatment Of Malignant GliomasApplication 19527494Pending
- Radiolabeled Mutagenized IL13Application 63726591Pending
Recent research by its founders
- Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine glioma20262 cites
- Abstract 1270: Immunotoxin GB13 Targets GBM and H3.3K27M DIPG with the activation of Golgi-to-ER retrograde transport pathways.20260 cites
- DDDR-69. Discovery, validation and deployment of a molecular signature of vulnerability to GB13 in an early stage GBM clinical trial20250 cites
Related companies, and why
- THE TINY CARGO COMPANYSimilar federal contract value in Biotech · $210K in contracts
- Ursa AnalyticsSimilar federal contract value in Biotech · $205K in contracts
- Avidity BiosciencesSimilar federal contract value in Biotech · $200K in contracts
- Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
- Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
- GEOVAX, INC.Similar federal contract value in Biotech · $198K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .